Dr. Philip M. Arlen gives scientific presentation in 5th Annual Neoantigen Based Therapies Summit 2020
Dr. Philip M. Arlen gives scientific presentation in 5th Annual Neoantigen Based Therapies Summit, entitled...
Dr. Philip M. Arlen gives scientific presentation in 5th Annual Neoantigen Based Therapies Summit, entitled...
Dr. Philip M Arlen, MD, President and CEO is Presenting the Following Talk at the...
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody. READ FULL ARTICLE
Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...
Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
Ariel Cahill Hollinshead Hyun, PhD, a pioneering cancer researcher whose work contributed to the foundation...
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...